



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/744,875	04/30/2001	Kenneth S. Zuckerman	USF-T176X	8728
23557 7	590 04/27/2005		EXAMINER	
	HIK LLOYD & SALIW	MCGARRY, SEAN		
PO BOX 1429	NAL ASSOCIATION 50		ART UNIT	PAPER NUMBER
GAINESVILLE, FL 32614-2950			1635	

DATE MAILED: 04/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)	
Advisory Action	09/744,875	ZUCKERMAN ET AL.	
Before the Filing of an Appeal Brief	Examiner	Art Unit	
	Sean R. McGarry	1635	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence ado	lress
THE REPLY FILED 14 April 2005 FAILS TO PLACE THIS APP			
 The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Notal Request for Continued Examination (RCE) in compliant time periods: The period for reply expires 3 months from the mailing date of this continued in the period for reply expires on (1) the mailing date of this continued in the period for reply expires on (1) the mailing date of this continued in the period for reply expires on (1) the mailing date of this continued in the period for reply expires on (1) the mailing date of this continued in the period for reply expires on (1) the mailing date of this continued in the period for reply expires on (1) the mailing date of this continued in the period for reply expires on (1) the mailing date. 	wing replies: (1) an amendment, aff office of Appeal (with appeal fee) in concession of the reply must be of the final rejection.	idavit, or other evider compliance with 37 C ust be filed within one	nce, which FR 41.31; or (3) of the following
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7 Extensions of time may be obtained under 37 CFR 1.136(a). The date	later than SIX MONTHS from the mailing (b). ONLY CHECK BOX (b) WHEN THE 06.07(f).	g date of the final rejecting FIRST REPLY WAS For the same of the appropriation of the approp	ion. FILED WITHIN ate extension fee
have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	stension and the corresponding amount shortened statutory period for reply origing than three months after the mailing da	of the fee. The approprinally set in the final Offi	riate extension fee ice action; or (2) as
2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any external a Notice of Appeal has been filed, any reply must be filed AMENDMENTS	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	ns of the date of ne appeal. Since
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE belo (c) They are not deemed to place the application in be appeal; and/or (d) They present additional claims without canceling a	onsideration and/or search (see NO ow); tter form for appeal by materially recorresponding number of finally rej	TE below); ducing or simplifying	
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1 4. The amendments are not in compliance with 37 CFR 1.1		mnliant Amendment	(PTOL-324)
5. Applicant's reply has overcome the following rejection(s)		mphane / michaniche	(1 102-024).
6. Newly proposed or amended claim(s) would be a non-allowable claim(s).	llowable if submitted in a separate,	timely filed amendme	ent canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: 8-13,20,27,28,64 and 65. Claim(s) objected to: 21. Claim(s) rejected: 22-26 and 29.	vided below or appended.	ll be entered and an e	explanation of
Claim(s) withdrawn from consideration: <u>1, 16, 19, 30, 32-AFFIDAVIT OR OTHER EVIDENCE</u>	35, 41-46, 50-63, and 66-77.		
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 	d sufficient reasons why the affidav	it or other evidence is	s necessary and
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to a showing a good and sufficient reasons why it is necessar. 10. The affidavit are attached to the sufficient reasons.	overcome <u>all</u> rejections under appear y and was not earlier presented. S	al and/or appellant fa ee 37 CFR 41.33(d)(ils to provide a 1).
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attacl	ned.

U.S. Patent and Trademark Office PTOL-303 (Rev. 4-05)

13. Other: _____.

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:

12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). _

Sean R McGarry Primary Examiner Art Unit: 1635

Application No. 09/744,875

Continuation Sheet (PTO-303)

Continuation of 3. NOTE: The amendments of 4/14/05 would, if entered, overcome the rejections of record and render the claims examined in the previous Official Action allowable, however, the entry of the amnedments of the papers filed 4/14/05 would also cause rejoinder of the withdrawn methods claims. The rejoinder of the method claims would cause new considerations such as enablemen, under 35 USC 112 first paragrap, t of the claims drawn to methods of nucleic acid based therapy..